Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.

Trial Details

NCT ID
NCT06228053
Phase
PHASE2
Sponsor
Syntrix Biosystems, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • SX-682
  • Enzalutamide
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Minneapolis, Minnesota, United States|44.97997,-93.26384
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form prior to beginning study and un…
  • 2\. Diagnosis of mCRPC with (a) any histology, and (b) currently on or previously on abiraterone/prednisone (or abiraterone/dexamethasone) or darol…
  • rising PSA (a rising PSA requires at least 3 measurements obtained at least 1 week apart showing increase from nadir with the last level above 2 ng…
  • progression of new or existing bone or soft tissue metastatic lesions by CT, MRI or bone scan; no washout necessary.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →